In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
|Articles|May 5, 2014
Publications for Patients and Caregivers
The Leukemia & Lymphoma Society (LLS) is pleased to present the following updated publications for patients and caregivers
Advertisement
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
To view PDFs or order copies of these free publications in English or Spanish, use the links above. To access all of our free publications, visit
- (800) 955-4572
- Live chat
Advertisement
Related to this article
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.
Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know
3
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
4
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
5